13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002010850
Total reported value
$731.7M
$731.7M
19 檔
89.5%
At the close of Q4 2025, Decheng Capital LLC disclosed equity holdings valued at approximately $731.7M, spread across 19 reported holdings.
In Q4 2025, Decheng Capital LLC adopted a defensive or profit-taking posture, trimming 9 positions and completely liquidating 4 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including CGON, NUVB, UPB) accounted for 89.5% of total reported equity market value during Q4 2025.
Top Position Liquidated / Trimmed
MERUS N V
前期市值: $17.6M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 35.59% | -3.34% | — | |
| 2 | NUVB | Nuvation Bio Inc | Stock-Other | 31.28% | +3.31% | — | |
| 3 | UPB | Upstream Bio Inc | Stock-Other | 11.48% | -1.13% | -4.33% | |
| 4 | AARD | Aardvark Therapeutics Inc | Stock-Other | 6.92% | +0.85% | — | |
| 5 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 2.87% | -0.77% | +16.22% | |
| 6 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 2.79% | -0.75% | -9.89% | |
| 7 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.14% | -0.03% | -4.76% | |
| 8 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.74% | +0.40% | -1.10% | |
| 9 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 1.64% | +0.63% | — | |
| 10 | EQ | Equillium Inc | Stock-Other | 0.93% | +0.60% | — | |
| 11 | ✓ | Beyondspring Inc Shs | Stock-Other | 0.83% | -0.03% | -11.32% | |
| 12 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.58% | — | -35.17% | |
| 13 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.57% | -0.29% | EXIT | |
| 14 | AURA | Aura Biosciences Inc | Stock-Other | 0.26% | — | -30.08% | |
| 15 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.24% | +0.41% | — | |
| 16 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.05% | +0.06% | — | |
| 17 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.04% | — | -52.22% | |
| 18 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.03% | — | — | |
| 19 | RZLT | Rezolute Inc | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NUVB | Nuvation Bio Inc | +14.5% | — | Unchanged |
| 2 | LYEL | Lyell Immunopharma, Inc. | +1.2% | +16.22% | Add |
| 3 | UPB | Upstream Bio Inc | +0.7% | -4.33% | Trim |
| 4 | RCUS | Arcus Biosciences Inc | +0.4% | -1.10% | Trim |
| 5 | RVMD | Revolution Medicines Inc | +0.4% | -4.76% | Trim |
| 6 | ACRS | Aclaris Therapeutics Inc | +0.3% | — | Unchanged |
| 7 | NUVB-WS | Nuvation Bio Inc -cw27 | 0% | — | Unchanged |
| 8 | RZLT | Rezolute Inc | -0.1% | — | Unchanged |
| 9 | PYXS | Pyxis Oncology Inc | -0.1% | — | Unchanged |
| 10 | FDMT | 4d Molecular Therapeutics In | -0.1% | -52.22% | Trim |
| 11 | ZNTL | Zentalis Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 12 | EQ | Equillium Inc | -0.2% | — | Unchanged |
| 13 | AURA | Aura Biosciences Inc | -0.3% | -30.08% | Trim |
| 14 | KRYS | Krystal Biotech Inc | -0.4% | -46.44% | Trim |
| 15 | CRNX | Crinetics Pharmaceuticals In | -0.5% | -35.17% | Trim |
| 16 | NAMS | NewAmsterdam Pharma Company N.V. | -0.5% | -9.89% | Trim |
| 17 | ✓ | Beyondspring Inc Shs | -0.5% | -11.32% | Trim |
| 18 | AARD | Aardvark Therapeutics Inc | -2.2% | — | Unchanged |
| 19 | CGON | Cg Oncology Inc | -9.2% | — | Unchanged |
| 20 | ✓ | Merus N V | — | EXIT | Sold out |
| 21 | ✓ | Moonlake Immunotherapeutics | — | EXIT | Sold out |
| 22 | ILMN | Illumina Inc | — | EXIT | Sold out |
| 23 | GRAL | Grail Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Decheng Capital LLC reported a total U.S. public equity portfolio value of $731.7M across 19 disclosed positions in Q4 2025.
During Q4 2025, Decheng Capital LLC's top holdings by market value included CGON (35.6%)、NUVB (31.3%)、UPB (11.5%). The largest single position, CGON, represented 35.6% of total portfolio value.
In Q4 2025, Decheng Capital LLC made 14 total portfolio adjustments, initiating 0 new buys, adding to 1 positions, trimming 9 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.